LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company, announced that its Venezuelan operating affiliate, LataMed AI VE, will be featured in an interview in ES Salud Magazine, a healthcare-focused publication. The feature, expected to be published in the July 2026 edition, will include an editorial profile and interview discussing the Company’s healthcare technology initiatives, digital healthcare ecosystem strategy, and ongoing efforts to improve healthcare accessibility throughout Latin America.
According to the Company, it has received a formal invitation from the publisher to participate in a broader editorial feature package expected to include coverage through both ES Salud Magazine and Eva's Magazine. The feature is anticipated to be distributed through multiple print, digital, social media, and online publication channels, providing a significant opportunity to increase visibility among healthcare professionals, industry participants, and other stakeholders.
Management stated that the publication will allow LataMed AI to discuss its evolving healthcare platform, including telehealth infrastructure, healthcare coordination technologies, payment accessibility initiatives, insurance integration opportunities, pharmacy-related services, and artificial intelligence-driven healthcare solutions currently under development. The feature is expected to highlight the Company’s broader vision of developing an integrated healthcare ecosystem designed to improve accessibility, coordination, and engagement for patients, healthcare providers, and other stakeholders across emerging markets.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., emphasized the importance of industry engagement: “We appreciate the opportunity to share our vision for technology-enabled healthcare solutions and discuss the initiatives we are currently advancing throughout Latin America. We believe healthcare accessibility, coordination, and patient engagement remain important challenges across many markets, and we welcome opportunities to participate in industry discussions regarding the role of technology in addressing those challenges.”
The Company expects the feature to be published during July 2026 and intends to provide additional updates once publication details have been finalized. For additional information, visit https://latamed.ai or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
